Stock Ratings / Health Care / NATR / insiders

BBOT (37) KRRO (44) SLGL (54) KROS (66) ⌘ Pro Terminal →

Nature's Sunshine Products Inc. (NATR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$12.25 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.22

Nature's Sunshine Products Inc. (NATR) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $216.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NATR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $12.25 (-0.24% 1D, market cap $216.1M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, NATR ranks #103 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NATR compare to BBOT and KRRO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C+ (68/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $216.5M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NATR?

▼

Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.22 (-0.23%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NATR)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY NATR SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 6% FCF Margin ($28.8M FCF) & 72.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$12.71-1.3% Next Q

Q2 (-2Q)

Grade B$12.55-2.2% Next Q

Q3 (-1Q)

Grade B$12.27-0.2% Next Q

Current

Grade C+$12.25+1.8% Hist 90D α

Trajectory: B+ (76) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NATR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, NATR faces multiple-compression risk if 11.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.04) or 200D SMA ($20.50) invalidates the momentum regime and cuts Target Base ($12.80) toward Bear Floor ($9.98).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NATR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NATR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NATR Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NATR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NATR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NATR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NATR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.94%▲ RESISTANCE BREAKOUT

2026-11-02O $12.27H $12.55L $12.25C $12.25VOL 13.3K

RES: $11.09SUP: $11.39SMA50: $13.04SMA200: $20.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NATR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NATR Butterfly Map → + Track NATR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

0.9%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NATR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NATR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NATR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NATR)

Health Care Rank #103 of 1016 ⚔️ BBOT vs NATR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NATR vs. BBOT, KRRO, SLGL, KROS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nature's Sunshine Products Inc. (NATR) ranks #103 by composite RQD confidence (68/100, grade C+) and #564 by equity capitalization ($216.1M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. NATR currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NATR ACTIVE Nature's Sunshine Products Inc.	C+	68/100	11.1x	72.4%	28.9%	-0.24%	$216.1M	Benchmark Subject
BBOT BridgeBio Oncology Therapeutics Inc.	D-	37/100	—	—	-35.0%	-2.96%	$216.5M	/bbot-vs-natr →
KRRO Korro Bio Inc.	D	44/100	—	—	-35.0%	+0.81%	$209.1M	/krro-vs-natr →
SLGL Sol-Gel Technologies Ltd.	D+	54/100	—	—	-35.0%	-0.45%	$224.8M	/slgl-vs-natr →
KROS Keros Therapeutics Inc.	C+	66/100	—	—	85.0%	-2.82%	$225.2M	/kros-vs-natr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000275053

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported GAAP revenue of $480.1M (+5.7% vs. FY2024 revenue of $454.4M , and +7.8% cumulative change since FY2023) , GAAP net income of $19.5M, operating cash flow of $35.3M, and free cash flow of $28.8M (+101.3% YoY). On the balance sheet, NATR closed FY2025 with $261.1M in total assets against $0 in total debt (Altman Z-Score: 4.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$480.1M	$19.5M	$35.3M	$28.8M	$261.1M	—
FY2024 (FY)	2024-12-31	$454.4M	$7.7M	$25.3M	$14.3M	$240.9M	—
FY2023 (FY)	2023-12-31	$445.3M	$15.1M	$41.2M	$41.2M	—	—

3. NATR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NATR compare to BBOT and KRRO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NATR?

Where is NATR trading relative to its 50-day, 200-day, and 52-week technical levels?

NATR last traded at $12.25 (-0.24% on volume of 99,356 shares), positioning the stock -6.06% below its 50-day simple moving average ($13.04) and -40.24% below its 200-day simple moving average ($20.50). Across its 52-week range of $12.00 to $28.14, NATR sits at the 1.5% percentile with a 14-day RSI of 41.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($11.47 to $13.03).

NATR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are NATR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NATR leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: NATR RQD Cockpit NATR 12M Forecast NATR Earnings & Move NATR Dividends & DRIP NATR Insiders & 13F NATR Whale Options NATR Profit Sankey NATR News & Why

Sector Peer Dials

Compare →

BBOT D-

BridgeBio Oncology Therapeutics Inc.

Sol-Gel Technologies Ltd.

54 /100

KROS C+

Keros Therapeutics Inc.

Akebia Therapeutics Inc.

57 /100

NATR Core Snapshot

Market Cap $216.1M

Trailing / Fwd P/E 11.1x / 10.3x

Gross Profit Margin 72.4%

Return on Capital (ROIC) 28.9%

Free Cash Flow Yield 13.35%

12M Base Price Target $12.80

FREE TRADER TOOLS

Own NATR Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With NATR → 🏆 Trade NATR in $100K Prop Arena →

NATR Wire

Why It Moved →

Direct Company Event Yahoo Finance • 6h ago

3 Reasons to avoid NATR and 1 stock to buy instead

Direct Company Event TradingView • 9h ago

Nature's Sunshine Products, Inc. Estimates – NASDAQ:NATR

Peer / Ecosystem Wire Yahoo Finance • 12h ago

Nature’s Sunshine Sets Third Quarter 2026 Conference Call for Wednesday, November 4, 2026, at 5:00 p.m. ET

Direct Company Event https://www.siam.in/ • 15h ago

Nature's Sunshine Products (NATR) Edges Higher as Shares Hold Above $12.50 - Conversion Trade

Direct Company Event Stock Traders Daily • 18h ago

(NATR) Risk Channels and Responsive Allocation

ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

NATR — Nature's Sunshine Products Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating assigns NATR a score of 68 and a letter grade of C+, with a verdict label of "Roarable Hold — Upper Neutral / Watch for Breakout" (per the Roarable RQD rating). Across the five pillars:

Fundamental cash engine (16 / 20): The rating cites ROIC of 28.9% and an FCF yield of 13.35% (per the Roarable RQD rating and market data). This is the strongest contributor to the score and suggests the business generates meaningful returns on invested capital relative to its market value.
Whale 13F flow (6 / 20): Institutional accumulation and options positioning score low. Per the source, the holders section is empty, so the basis for this weak score cannot be verified from the supplied material.
Insider conviction (18 / 20): The highest pillar, reflecting SEC Form 4 and Congressional PTR cluster flow (per the Roarable RQD rating). The underlying transaction detail is not provided in the source data.
Macro regime fit (12 / 20): Beta of 1.0 and sector sensitivity are cited (per the Roarable RQD rating and market data). A beta of 1.0 implies market-level sensitivity, not a defensive or aggressive profile.
Forensic balance sheet (16 / 20): Altman Z-Score of 4.33, Piotroski F-Score of 8/9, and Debt/Equity of 0.5 (per the Roarable RQD rating).

For a prospective investor, the upside case rests on the cash-generation metrics and the strong balance-sheet pillar, against valuation that appears low on the market data (P/E TTM of 11.1, EV/EBITDA of 4). The tradeoffs are thin operating margin (5.2%), weak institutional flow, and a verdict that stops short of a buy signal. The "Watch for Breakout" label indicates the rating is conditional on future confirmation rather than already triggered.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
12.42	$216.1M	11.1	10.3	4	1.11	0%	1.0	$12 - $28.14	28.9%

Business

Nature's Sunshine Products Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The source data does not describe its products, customers, or revenue model. Market capitalization is reported as $0.2B (per the company profile). Gross margin is 72.4% (per market data), indicating the reported business carries a high gross margin profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$480.1M	$24.7M	$19.5M	N/A	$28.8M	$93.9M	N/A
FY 2024	$454.4M	$20.1M	$7.7M	N/A	$14.3M	$84.7M	N/A
FY 2023	$445.3M	$18.7M	$15.1M	N/A	$41.2M	N/A	N/A

Revenue rose from $445.3M (FY 2023) to $480.1M (FY 2025) per the SEC financials. Net income was $19.5M in FY 2025, up from $7.7M in FY 2024 but below $15.1M in FY 2023 in the earlier year's terms of comparison. Reported operating margin is 5.2% and net margin is 4.1% (per market data). ROIC is 28.9% and the Altman Z-Score is 4.33 with a Piotroski F-Score of 8/9 (per the Roarable RQD rating). Debt/Equity of 0.5 is cited (per the Roarable RQD rating); the debt figures themselves are not available in source data.

Recent Catalysts & News Wire Analysis

Five news items are provided (per the recent news section):

Yahoo Finance (YELLOW, MARKET WIRE): "3 Reasons to avoid NATR and 1 stock to buy instead." The article body is not included in the source data.
TradingView (YELLOW, MARKET WIRE): "Nature's Sunshine Products, Inc. Estimates." Body not provided.
Yahoo Finance (YELLOW, MARKET WIRE): Announces a third-quarter 2026 conference call for Wednesday, November 4, 2026, at 5:00 p.m. ET. This is the only dated company event in the source data.
Stock Traders Daily (RED, RISK WATCH): "(NATR) Risk Channels and Responsive Allocation." Flagged as a risk watch item; body not provided.
TradingKey (GREEN, CATALYST): "Top U.S. Stock Gainers: Biggest Price Increases," flagged as a catalyst. Body not provided.

A separate item carries a summary reporting shares holding above $12.50, but its headline and summary text are not corroborated by the price data (price is 12.42). The butterfly supply-chain graph reports no links and no proprietary signals (per the Butterfly Supply-Chain Graph).

Open Questions

What drives the FY 2024 net income low ($7.7M) relative to operating income ($20.1M), and what explains the FY 2025 recovery?
What is the company's total debt and cash position, given that debt is not reported in the source data?
What are the EPS figures for each reported period, since EPS is listed as N/A across all three filings?
What insider and institutional transactions underlie the insider (18/20) and whale-flow (6/20) pillar scores?
What is the content of the third-quarter 2026 results expected on November 4, 2026?

NATR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nature's Sunshine Products Inc. (NATR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NATR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 6h ago

3 Reasons to avoid NATR and 1 stock to buy instead

Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 9h ago

Nature's Sunshine Products, Inc. Estimates – NASDAQ:NATR

TradingView report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 12h ago

Nature’s Sunshine Sets Third Quarter 2026 Conference Call for Wednesday, November 4, 2026, at 5:00 p.m. ET

Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 15h ago

Nature's Sunshine Products (NATR) Edges Higher as Shares Hold Above $12.50 - Conversion Trade

https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 18h ago

(NATR) Risk Channels and Responsive Allocation

Stock Traders Daily report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 21h ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Nature's Sunshine Products (NATR) Edges Higher to $12.71 as Buyers Hold the Line Above Support - Continuation Pattern Picks

https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NATR Bull vs. Bear Conversation Board — What's Your Call at $12.25?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NATR 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $13.26 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is NATR (C+ • RQD 68/100) a Buy at $12.28?

Welcome to the NATR (Nature's Sunshine Products Inc.) Roar Pit. Current RQD Composite is 68/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (28.9% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.07 (-18.0%)

Spot @ $12.28

Pump the brakes on NATR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on NATR, but look at what you are paying: 11.1x trailing P/E with 72.4% gross margins. Unless Nature's Sunshine Products Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.47 (+26.0%)

Spot @ $12.28

NATR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on NATR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.28 (52-wk range $11.31 - $14.01), any beat on forward guidance forces shorts and underweight funds to chase.